CORRECTION: CLARIFICATION RELATED TO THE NOTICE OF ANNUAL GENERAL MEETING
Biohit Oyj April 5, 2013 at 4:30 P.M. local time (EET)
Resolution on the use of the result shown on the Balance Sheet and on dividend payment
The Board of Directors proposes that the profit for the financial period ended on 31st of December 2012 be recorded in the profit and loss account.
The Board of Directors proposes that on the basis of the financial statements to be adopted for the financial period ended on 31st of December 2012, a dividend of EUR 0,4964 (previously proposed EUR 0,49) per each A share and EUR 0,4998 for each B share be paid. Dividend will be paid to shareholders recorded in the company's shareholder register on the matching day, 11th of April 2013. The Board of Directors proposes that the dividend will be paid out on 18th of April 2013.
Additional information:
CEO Semi Korpela, Biohit Oyj
Tel. +358 9 773 861
semi.korpela@biohit.fi
www.biohit.fi
Biohit in brief
Biohit Oyj is a Finnish biotechnology company operating globally that was established in 1988. Biohit's mission is "Innovating for Health". The purpose of the company is to take social responsibility and produce innovation, new technologies and analysis systems for use in medicine, research institutions and industry, helping to promote research and diagnostics and to improve the quality of life of people by means of preventing disease, human suffering and financial loss. We are committed to social responsibility and it is our duty to spread knowledge about the Group 1 human carcinogen, acetaldehyde, and innovate and develop the marketing and availability of our products and services. Biohit is headquartered in Helsinki and its subsidiaries are located in China and the United Kingdom. Since 1999, Biohit's Series B shares (BIOBV) have been listed in the NASDAQ OMX Helsinki Oy Small cap/Healthcare sector.